Delving into the Latest Updates on Olverembatinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Orebatinib, Oribatinib, 奥瑞巴替尼

+ [15]

Target

Bcr-Abl T315I x c-Kit

Action

inhibitors

Mechanism

Bcr-Abl T315I inhibitors(BCR-ABL T315I mutation inhibitors), c-Kit inhibitors(Stem cell growth factor receptor inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [4]

Active Indication

Aggressive-Phase Chronic Myelocytic LeukemiaChronic phase chronic myeloid leukemiaSDH-deficient Gastrointestinal Stromal Tumors+ [12]

Inactive Indication-

Originator Organization

Guangzhou Shunjian Biomedical Technology Co. Ltd.

Active Organization

Ascentage Pharma Group, Inc.

Innovent Biologics, Inc.

Guangzhou Shunjian Biomedical Technology Co. Ltd.

+ [1]

Inactive Organization-

License Organization

Ascentage Pharma Group International Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

Innovent Biologics, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

China (24 Nov 2021),

Aggressive-Phase Chronic Myelocytic LeukemiaChronic phase chronic myeloid leukemia

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC31H35F3N6O7S2

InChIKeyLEVIGHXVOVROGW-UHFFFAOYSA-N

CAS Registry1421783-64-3

This open-label, non-randomized, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL). Patients are stratified by genetic alteration: those with ABL class fusions (ABL1, ABL2, PDGFRA, PDGFRB) receive olverembatinib, while those with JAK pathway alterations (CRLF2 rearrangement, JAK mutation/fusion, EPOR fusion, SH2B3 deletion, IL7R mutation) receive Gecacitinib. Both groups undergo sequential induction, consolidation, intensification, and maintenance therapy as per protocol.
The primary endpoint is the rate of flow cytometry minimal residual disease (MRD)-negative complete remission (CR MRD-) at 3 months after induction therapy. Secondary endpoints include overall complete remission rate, NGS MRD-negative CR rate at 3 months, overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), cumulative incidence of relapse, and 60-day mortality.

Start Date30 May 2026

Sponsor / Collaborator

Hematology Hospital of Chinese Academy of Medical Sciences

ChiCTR2600124345

/ Not yet recruitingEarly Phase 1IIT

Exploratory study of PULSAR radiotherapy concurrent with apalutamide and toripalimab combined with TAS-102 for the treatment of liver metastases from pMMR/MSS colorectal cancer in the third-line or higher settings

Start Date11 May 2026

Sponsor / Collaborator

The Second Affiliated Hospital of Nanchang University

100 Clinical Results associated with Olverembatinib

Login to view more data

100 Translational Medicine associated with Olverembatinib

Login to view more data

100 Patents (Medical) associated with Olverembatinib

Login to view more data

111

Literatures (Medical) associated with Olverembatinib

01 Jun 2026·TRANSPLANT IMMUNOLOGY

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy

Article

Author: Ji, JiaJuan ; Fan, ShengJin ; Zhu, YuTing ; Zhao, YanQiu ; Ding, PeiWen ; Luo, Dan ; Guo, Dan ; Liu, Jie

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and the resulting fusion proteins with abnormal tyrosine kinase activity. The treatment of CML includes allogeneic hematopoietic stem cell transplantation (allo-HSCT) and TKI drug therapy. The BCR::ABL1 T315I mutation in CML leads to resistance to first- and second-generation tyrosine kinase inhibitors (TKIs), but is sensitive to two third-generation TKIs, olverembatinib and ponatinib. Olverembatinib, an oral third-generation BCR::ABL1 TKI, has preclinical activity against T315I-mutated CML. Here, we present a case of a CML patient with the T315I mutation who experienced late relapse with blast crisis 10 years after allo-HSCT. Following hematologic recovery and achievement of major molecular response (MMR) through induction therapy, the patient underwent a second allo-HSCT from his haploidentical sister. After successful engraftment, the patient received regular consolidation maintenance therapy with olverembatinib.

01 Jun 2026·JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacological targeting of the mycothiol cysteine ligase MshC in Mycobacterium abscessus

Article

Author: Liu, Yi ; Giannini, Greta Carola ; Nguyen, Thanh Quang ; Larrouy-Maumus, Gerald ; Kremer, Laurent ; Hamela, Claire ; Boeck, Lucas ; Pang, Luping

The prevalence of pulmonary diseases caused by Mycobacterium abscessus is on the rise and surpasses tuberculosis in many countries. However, intrinsic resistance of this pathogen to antibiotics profoundly limits our therapeutic arsenal, and new chemotherapeutic agents and targets are urgently needed. Mycothiol (MSH), the major thiol in mycobacteria, plays an important role in resistance to oxidative stress. Previous work in Mycobacterium smegmatis and Mycobacterium tuberculosis indicates that the ATP-dependent cysteine ligase MshC catalyzes the penultimate step in MSH biogenesis. Here, we investigated whether MshC represents a potent drug target in M. abscessus. CRISPRi was used to demonstrate that mshC is essential in vitro and during infection in zebrafish larvae. Subsequently, in silico drug screening identified three potential MshC-binding molecules, namely rebastinib, olverembatinib and SB-224289, significantly inhibiting M. abscessus growth and MSH production. Spontaneous missense mutations in MshC generated cross-resistance to all three compounds. Mapping the mutations conferring resistance on a MshC three-dimensional homology model defined the enzyme catalytic site as the potential drug binding cavity. Additionally, overexpression of mshC in a susceptible M. abscessus strain increased resistance levels to rebastinib, olverembatinib and SB-224289, but not to rifabutin. Conversely, reduced mshC expression levels in the CRISPRi mutant increased susceptibility to the inhibitors. Systematic assessment of olverembatinib and SB-224289 in combination with 18 additional drugs revealed distinct synergistic and antagonistic interactions. These results emphasize a yet unexploited chemical structure class against M. abscessus and highlight the potential of targeting the MSH pathway for future translational developments against M. abscessus lung diseases.

12 May 2026·Leukemia & Lymphoma

Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity

Article

Author: Zhang, Ping ; Wang, Xiao-dan ; Liao, Ying-xi ; Wang, Xiao-xu ; Li, Shan ; Miao, Wen-juan ; Tian, Ji-xin ; Sun, Xin-yuan ; Liu, Dong-xue

The novel tyrosine kinase inhibitors (TKIs), characterized by superior potency and selectivity against BCR-ABL1 kinase, are increasingly administered concomitantly with high-dose methotrexate (HD-MTX) for BCR-ABL1-positive acute lymphoblastic leukemia. However, data on TKI-MTX drug interactions remain scarce. We retrospectively analyzed 49 adults who received HD-MTX, of whom 10 were co-treated with olverembatinib and 17 with flumatinib. MTX clearance was estimated using a population pharmacokinetic model. Olverembatinib significantly reduces MTX clearance (35.1% slower than no-TKI) and elevates 48-hour serum concentration above the safety threshold in 80% of cases, resulting in a 60% incidence of ≥ grade 2 nephrotoxicity and a 70% rate of acute kidney injury (AKI)-both markedly higher than with HD-MTX alone (4.6% and 27.3%, respectively). Flumatinib likewise lowered MTX clearance and raised ≥ grade 2 nephrotoxicity to 29.4%, yet neither effect reached statistical significance. Temporary withdrawal of olverembatinib before HD-MTX infusion may prevent MTX-related nephrotoxicity.

254

News (Medical) associated with Olverembatinib

02 Sep 2026

·www.biospace.com

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York. Citi’s 2026 Biopharma Back to School Conference Format: Fireside chat and one-on-one investor meetings Date and Time: Wednesday, September 9, 2026, 4:20 p.m. to 4:55 p.m. ET Location: JW Marriott Essex House, 160 Central Park South, New York, NY H.C. Wainwright 28th Annual Global Investment Conference Format: Company presentation and one-on-one investor meetings Date and Time: Monday, September 14, 2026, 9:00 a.m. to 9:30 a.m. ET Location: Lotte New York Palace Hotel, 455 Madison Avenue, New York, NY Deutsche Bank 2026 Healthcare Summit Format: Company presentation and one-on-one investor meetings Date: Wednesday, September 16 - Thursday, September 17, 2026 Location: Deutsche Bank Center, One Columbus Circle, New York, NY ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum Format: Company presentation and one-on-one investor meetings Date: Wednesday, September 23 - Thursday, September 24, 2026 Location: New York, NY Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their conference representative. About Ascentage Pharma Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders. ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3. The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Cautionary Note Regarding Forward-Looking Statements ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: ezstandalone.cmd.push(function () { ezstandalone.showAds(134); }); Sumedh Sunkaraneni Ascentage Pharma IR@ascentage.com +1 (301) 792-6286 Brian Korb astr partners brian.korb@astrpartners.com +1 (917) 653-5122

13 Aug 2026

·www.globenewswire.com

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in the Evercore ISI 2nd Annual China Biotech Summit, being held August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong. Management will participate in a fireside chat moderated by the Evercore research team and one-on-one investor meetings during the conference. Fireside Chat Date: August 18, 2026Time: 7:45-8:00am Beijing TimeLocation: The Ritz-Carlton Shanghai, Pudong, Grand Ballroom 2 & 3 Investors interested in scheduling a meeting with the Ascentage Pharma management team should contact their Evercore representative. About Ascentage Pharma Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders. The Company’s first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3. The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/ Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this press release do not constitute profit forecast by the Company’s management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations:Sumedh Sunkaraneni Ascentage PharmaIR@ascentage.com+1 (301) 792-6286 Brian Korbastr partnersbrian.korb@astrpartners.com+1 (917) 653-5122

Phase 3Drug ApprovalPhase 2

10 Aug 2026

·www.pharmaceutical-technology.com

Innovent and Daiichi Sankyo sign deal for Vanflyta in China

The therapy received approval in China for use in combination with standard cytarabine and anthracycline induction. Credit: Bohbeh creations / Shutterstock.com. Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China. Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China. Vanflyta received approval in the country in June 2026 for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, as well as for maintenance monotherapy following consolidation chemotherapy. The indication covers treatment of adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (AML) as determined by an appropriate validated diagnostic test. Approval was based on data from the QuANTUM-First trial. Innovent Biologics executive director and chief commercial officer Vivian Zhang said: “Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence, including TYVYT (sintilimab injection), Halpryza (rituximab injection), olverembatinib, Fucaso (Equecabtagene Autoleucel Injection), Jaypirca (pirtobrutinib), and the addition of Vanflyta will further enhance our synergistic offerings.” “Vanflyta will be the 20th product in Innovent’s commercialised product portfolio. Through collaborative efforts, we aim to bring forward innovative medicines to benefit patients with cancer and further strengthen our leadership in oncology.” Daiichi Sankyo China president Michio Hayashi said: “The partnership with Innovent Biologics reflects our commitment to delivering innovation to patients in China. “By combining our research and development capabilities with Innovent’s commercial capabilities in China, we believe this collaboration can accelerate access to Vanflyta for patients with newly diagnosed FLT3-ITD-positive AML and ultimately help improve outcomes in this high-risk patient population.” Last month, Innovent Biologics agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to develop, research, manufacture and commercialise IBI355, also known as SP001, outside Greater China.

License out/inDrug Approval

100 Deals associated with Olverembatinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D12175	-	-	DB16185

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Aggressive-Phase Chronic Myelocytic Leukemia	China	Guangzhou Shunjian Biomedical Technology Co. Ltd.	24 Nov 2021
Chronic phase chronic myeloid leukemia	China	Guangzhou Shunjian Biomedical Technology Co. Ltd.	24 Nov 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
SDH-deficient Gastrointestinal Stromal Tumors	Phase 3	China	Ascentage Pharma Group, Inc.	11 Nov 2024
SDH-deficient Gastrointestinal Stromal Tumors	Phase 3	China	Guangzhou Shunjian Biomedical Technology Co. Ltd.	11 Nov 2024
Philadelphia chromosome positive chronic myelogenous leukemia	Phase 3	United States	Ascentage Pharma Group, Inc.	05 Feb 2024
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	United States	Ascentage Pharma Group, Inc.	31 Aug 2023
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	China	Ascentage Pharma Group, Inc.	31 Aug 2023
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	Australia	Ascentage Pharma Group, Inc.	31 Aug 2023
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	Czechia	Ascentage Pharma Group, Inc.	31 Aug 2023
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	France	Ascentage Pharma Group, Inc.	31 Aug 2023
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	Italy	Ascentage Pharma Group, Inc.	31 Aug 2023
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia	Phase 3	Romania	Ascentage Pharma Group, Inc.	31 Aug 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06423911 (POLARIS-2, ASCO2026)	Phase 3	Chronic phase chronic myeloid leukemia T315I mutation	270	Bosutinib	whrrwipzep(ymetslxzgy) = whmyotafqo ikzhmfgepl (mjksakwoqt )	Positive	29 May 2026
				Olverembatinib (T315I mutation)	mnvetfebeb(rlcjkelcla) = hxuqjwqnat tpvpcimwvz (ocyfbufrvl )
NCT04260022 (HQP1351CU101, ASCO2026)	Phase 1	Philadelphia positive acute lymphocytic leukaemia \| Blast Phase Chronic Granulocytic Leukemia	9	Olverembatinib + blinatumomab (R/R Ph+ BCP-ALL or CML-LBP)	albwlxptiq(wwtdrdmjxu) = Four patients experienced grade 3 AEs related to olverembatinib, including increased lipase, neutropenia, thrombocytopenia, and pancreatitis. pfmpvkyzrb (oiqodtpypq ) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	253	Olverembatinib (Philadelphia chromosome-positive acute lymphoblastic leukemia)	qcnxtmbmlq(hluyvmmmwt) = hozlqowcjc toiuwqufhr (ltczylraoe, 67.0 - 96.0) View more	Positive	29 May 2026
EHA2026	Not Applicable	Chronic Myelogenous Leukemia	60	Olverembatinib	wdtpxgaypg(zbzzxjvvkj) = Non-hematological toxicity with an incidence of more than 10 % included 24(45%) pigmented nevus, 10 (13.9%) infections, 6(10%) rash, 6(10%) myoarthritis. 4(6.7%) patients developed cardia-cerebrovascular events(1 angina, 1 cerebral infarction and 2 arrhythmias). ohsiigwrdw (awwhivuehv )	Positive	12 May 2026
NCT06423911 (POLARIS-2, EHA2026)	Phase 3	Chronic phase chronic myeloid leukemia	333	Olverembatinib	mnwjxbkqyj(bhtwexqakd) = mwejqqfbby vwuxcilwqk (nbnmubulav )	Positive	12 May 2026
				Bosutinib	mnwjxbkqyj(csoregenzd) = saxgucpeyc ctydejosqg (xymvxxeqjl ) View more
EHA2026	Not Applicable	Chronic phase chronic myeloid leukemia	105	Olverembatinib	pxfipdsuzs(wfyjphajmp) = lmsxjwfyyw enpbzsegru (zkjszhadsl ) View more	Positive	12 May 2026
				Original TKI therapy	pxfipdsuzs(wfyjphajmp) = nlmurmjdtd enpbzsegru (zkjszhadsl ) View more
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia	63	Olverembatinib	hgwbjahzhz(jsmjhpatbq) = hkzbtvetdu amopefqqjj (dltnevferk ) View more	Positive	06 Dec 2025
				original TKI therapy	hgwbjahzhz(jsmjhpatbq) = dimmmtxnqv amopefqqjj (dltnevferk ) View more
ASH2025 \| EBMT2025	Not Applicable	Blast Phase Chronic Granulocytic Leukemia	64	Olverembatinib	hcysyprsja(xxvrwonhwr) = Treatment-related adverse events in olverembatinib cohort 52.4% (11/21) of patients. Six (28.6%) developed grade 3/4 neutropenia. Cardiovascular Events were observed in two patients, including deep vein thrombosis (n=1) and pericardial effusion (n=1). cfgjkszrbm (zqrksucocj ) View more	Positive	06 Dec 2025
				1/2G-TKI
ASH2025	Not Applicable	Chronic Myelogenous Leukemia	167	Olverembatinib therapy	pxcdqnbvog(pmgaescorr) = jtawwqokit jugowttwjz (mohjezjtlw ) View more	Positive	06 Dec 2025
NCT03594422 (Signal Transduct Target Ther) Manual	Phase 1	SDH-deficient Gastrointestinal Stromal Tumors SDH deficient	66	Olverembatinib (TKI-failed, evaluable)	vmdixtqtiz(osrqqggeld) = eqhwvqnesb kulrwyhufn (rvyefucdwc, 9 - 43.7) View more	Positive	04 Nov 2025